Facts
as of Nov 16, 2026
About About Us Management Board of Directors Scientific Advisory Board Contact Us Celldex is pioneering new horizons in immunology to deliver life-changing therapies.
It is hiring: 12 open roles, 6 of them posted in the last 30 days.
- Legal name
- Celldex Therapeutics, Inc.
- Founded
- 2017
- Employees
- 1001-5000estimated range
- Open roles
- 12 in 6 citiesAlion job postings
- Register numbers
- NAME celldex therapeutics inc
- Website
- celldex.com
As of Nov 16, 2026, Alion lists 12 open roles at celldex. It was founded in 2017. The median pay stated in its open roles is $229k, across 10 postings that state pay.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Legal entity active
Celldex Therapeutics, Inc.
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Hiring at full speed: most open roles are fresh.
Biotech is the largest family, 23 of open roles.
6Posted in 30 days50% of open roles are fresh
8%Remote roles1 of 12
6Hiring offices
Can they hire you from United States?by your location
Likely
23 open roles are in your country: you apply locally, no move needed.
United States23On site
Remote, from elsewhere1Rare
No posting offers visa sponsorship. Remote roles: 1.
Time to fillmedian days to close a role
celldex23 days
Market, same roles31 days
Alion signals0-100
Demand9
Pay40
Your chance39
How badly they need people, whether they pay, how realistic getting in is.
Open roles over time−100%
Sep 21This week
Open roles a week: 18 then, 0 now
Where the openings areshare of open roles · trend
Biotech23▲
Operations19▼
Finance15▼
HR12
Industrial Engineering12▼
Management8▲
Degree asked
Bachelor's Degree 50%Doctoral Degree (PhD) 38%Associate's Degree 13%
Experience asked: 9.3 years on average, in 10 postings. 8 postings state a degree.
Benefits named in postingsshare of open roles
Equity12100%
Professional development867%
Home office18%
Contract type
Contract 1
Visa sponsorship: none statedRelocation: none stated
Source: the company's careers site, read by Alion several times a day; market medians from all open roles of the same family
What its postings pay, by level.
$229kMedianmarket estimate $215k
$131k – $245kTypical rangeUSD a year
$401kHighest paying roleVice President, Pharmacovigilance & Risk Management
Pay by levelmiddle half of stated pay, median marked · dashed: market median $215k
Senior3$213k$131k – $213k
Head+5$264k$229k – $349k
$0$100k$200k$300k$400k
Source: the pay stated in the company's postings, normalised to USD a year
Named in the work visa registers of United States.
2H-1B filings in 12 months
$128kMedian offered salary
12Open roles in United States
In the register as Celldex Therapeutics, Hampton, NJ
Other sponsors in the same field
US Department of Labor · latest filing Jan 6, 2026
Footprint
Hiring in 6 cities in 1 country.
6Cities
1Countries
HamptonBusiest site
Source: office addresses in postings and company registers
Ranked #3 by open roles among its 11 closest peers.
Source: Alion's similar-companies engine (industry segments, technologies, headquarters country, size)
Technologies named in job postings at celldex over the last 12 months, by layer, with the share of postings for each.
14Technologies in use
6Postings analysed
78/100Stack modernityAI adopter
Sign in to see how your skills match this stackSign In
Source: the technologies named in the company's postings and on its site
Milestones
Each milestone is dated by its source: registers, filings, the press
Newsroom
Sep 242026
Press release · The Globe and Mail
Detailed price information for Celldex Therapeutics (CLDX-Q) from The Globe and Mail including charting and trades.
Sep 242026
Press release · The Globe and Mail
Detailed price information for Celldex Therapeutics (CLDX-Q) from The Globe and Mail including charting and trades.
Sep 232026
News · YahooFinance
When biopharmaceutical companies advance platform technologies targeting complex immunological pathways, market participants must weigh clinical efficacy against the heavy capita…
Sep 222026
News · YahooFinance
Celldex Therapeutics (NASDAQ:CLDX) reported positive top-line results from its two Phase III EMBARQ-CSU studies of barzolvolimab in adults with chronic spontaneous urticaria, or…
Sep 222026
News · markets.businessinsider.com
Best-in-disease results showed rapid, profound, sustained efficacy, supporting barzolvolimab's potential to be a transformational therapy in CSUEM...
Sep 222026
News · thepharmaletter.com
Sources: the outlets named on each headline, each story once